Can a common antipsychotic keep cannabis users out of the ER?
NCT ID NCT07726069
First seen Jul 24, 2026 · Last updated Sep 02, 2026 · Updated 4 times
Summary
This trial tests whether giving patients a prescription for haloperidol to use as needed at home can help control symptoms of cannabinoid hyperemesis syndrome — a condition marked by severe nausea, vomiting, and abdominal pain from heavy cannabis use. The goal is to see if having the medication available reduces the number of return visits to the emergency department. One hundred adults diagnosed with the syndrome who are safe to go home will receive the prescription and be followed for symptom improvement and side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- haloperidol, an antipsychotic medication taken as needed for symptom control
- What this could lead to
- If it works, this could give patients a way to manage cannabinoid hyperemesis syndrome at home and reduce repeat emergency visits.
- What could go wrong
- This is a very early-phase trial with only 100 participants. Haloperidol can cause side effects like drowsiness, movement problems, or heart rhythm changes, and it may not prevent return ER visits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients must meet ALL of the following criteria: * Age ≥ 18 years * Primary ED complaints of acute or episodic nausea, vomiting, and/or abdominal pain * Self reported frequent cannabis use Patients must meet at least TWO of the following criteria: * History of recurrent, cyclical episodes of severe nausea and vomiting * Self-reported temporary symptom relief with hot showers or baths * Symptom onset or exacerbation following cannabis consumption Exclusion Criteria: * Patients with imaging or lab findings suggestive of an alternative etiology that would explain their symptoms * Already on dopamine agonist/antagonist therapy for another condition * Parkinson's disease * Lewy body dementia * Men with QTc \> 450 * Women with QTc \> 460 * Patients with documented allergy to haloperidol * Patients with known functional prolactinomas * Patients who are breastfeeding * Patients under the age of 18 * Patients who are pregnant * Patients who are in the prison system * Patients who are unable to consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabinoid hyperemesis syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Illinois Hospital
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.